Global Urology Devices Market Outlook
Revenue, 2024
$34.7B
Forecast, 2034
$70.2B
CAGR, 2025 - 2034
7.3%
The Urology Devices industry revenue is expected to be around $37.2 billion in 2025 and expected to showcase growth with 7.3% CAGR between 2025 and 2034. The urology devices market has established itself as a fundamental component for delivering advanced urological care because of increasing kidney stone cases and prostate disorders and urinary tract infections and urinary incontinence and patient demand for minimally invasive procedures and better life quality. The hospital and ambulatory surgical center sector along with other institutional users make up 88.7% of total market demand because these facilities operate at high volumes which determines product requirements and procurement timelines and maintenance agreements.
Urology devices include a range of the urology equipment the urology diagnostic devices and the urological consumables. Manufacturers build urology devices to give the accuracy the steady performance and the comfortable ergonomics, for the patients. Urology devices work in the diagnostic the therapeutic and the monitoring steps. I have seen doctors use urology devices for procedures. Key applications of urology devices cover the kidney stone management with laser lithotripsy systems the prostatic hyperplasia treatment, the urinary incontinence solutions, the urologic oncology interventions and the reconstructive surgeries. Hospitals & Ambulatory Surgical Centers and office based practices use urology devices. Recent trends such as device miniaturization, integration of digital imaging and analytics, expansion of single use and disposable device formats, and wider adoption of minimally invasive urology techniques are collectively accelerating demand for advanced urology devices, reinforcing their strategic importance in modern urology departments worldwide.
Market Key Insights
The Urology Devices market is projected to grow from $34.7 billion in 2024 to $70.2 billion in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Kidney Diseases, Urological Cancer, and Benign Prostatic Hyperplasia.
Boston Scientific, BD, and B. Braun Melsungen AG are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Urology Devices market and are expected to observe the growth CAGR of 4.7% to 7.0% between 2024 and 2030.
The market research predicts that India, Brazil and Mexico will experience the highest growth rates at 8.4% to 10.1% CAGR.
Transition like Shift To Minimally Invasive Care is expected to add $5 billion to the Urology Devices market growth by 2030
.The Urology Devices market will experience $35.5 billion growth during 2024 to 2034 because manufacturers focus on developing products for Urological Cancer & Pelvic Organ Prolapse Application.
With
rising burden of urological chronic diseases and expanding geriatric population accelerating adoption of advanced urology devices, and
Technological convergence around minimally invasive urologic interventions transforming precision, safety, and efficiency of urology devices, Urology Devices market to expand 102% between 2024 and 2034.
Opportunities in the Urology Devices
The healthcare sector in emerging economies has also started to implement urology devices and analytics platforms which connect operating rooms to ambulatory surgery centers. The combination of government hospital modernization initiatives and expanded insurance coverage and international partnerships between local distributors and global manufacturers has accelerated the adoption of smart urology equipment. The market will experience its most significant expansion through integrated diagnostic and therapeutic instrument systems which include software platforms that unite capital equipment with growing consumables needs and digital health solutions for urology care delivery.
Growth Opportunities in North America and Asia-Pacific
The main market for urology devices in North America exists within Hospitals & Ambulatory Surgical Centers because these facilities adopt minimally invasive urology technology and advanced endoscopic systems and high value urology diagnostic equipment; Dialysis Centers show increasing importance because chronic kidney disease and urological complications that occur with it require more procedures; the main market potential exists in two region's: hospitals can use their high volume programs to establish premium positions for kidney stone management devices and urinary incontinence treatment solutions and ASCs need unique product lines for stone and BPH and oncology procedures and urologists should work with dialysis centers to develop integrated care pathways for managing long term catheters and stents and drainage systems. The market requires smart connected urology devices and clinical decision support tools and service based contracts that match value based reimbursement models because multinational manufacturers and mid sized innovators compete intensely for market share. New market participants and local businesses must develop creative financing strategies and package capital and consumable products together with fast device replacement and educational partnerships with major healthcare facilities and ASC networks to stay competitive.
The Hospitals & Ambulatory Surgical Centers throughout Asia Pacific serve as the primary end users for urology devices because of expanding tertiary care facilities and increasing day care surgery operations and medical tourism growth. The Others segment includes Dialysis Centers and specialized urology clinics which gain strategic value because diabetes and hypertension and stone disease require integrated renal urology care. The market demands endoscopic urology devices and kidney stone management devices which should be designed for different hospital budget levels. The market requires affordable urology diagnostic equipment and portable imaging solutions for rural and semi urban facilities and single use or hybrid infection control solutions for urinary incontinence treatment and BPH interventions. The competition between global medtech companies and domestic manufacturers requires hospitals and ASC networks and dialysis chains to establish their market position through reliable products and extensive service networks and educational programs instead of using price as their main differentiator.
Market Dynamics and Supply Chain
01
Driver: Rising burden of urological chronic diseases and expanding geriatric population accelerating adoption of advanced urology devices
The rising number of kidney stone cases and urologic cancers and benign prostatic hyperplasia cases also drives hospitals and specialized centers to perform more procedures which leads to increased demand for advanced urology equipment. The growing need for endourology devices also drives manufacturers to create digital flexible ureteroscopes and high power laser lithotripters and disposable cystoscopes for treating complex stone and tumor cases. The aging population grows because people live longer which leads to more elderly patients who need ongoing treatment for urinary incontinence and neurogenic bladder and obstructive urinary issues. The market responds to this trend through the development of ergonomic catheters and long term stent solutions and connected urinary incontinence management systems for home and long term care environments. The combination of 3D visualization and low dose fluoroscopy in advanced urological imaging systems enables better early detection and safer procedures for elderly patients which maintains long term market demand for minimally invasive urology equipment worldwide.
The market now also depends on the combination of optical technology with small sensor devices and digital navigation systems which improves minimally invasive urology tools for stone disease treatment and prostate disorders and uro oncology care. The next generation of platforms unites HD visualization with laser energy delivery and smart irrigation systems into one endoscopic workspace which leads to better stone removal success rates and shorter procedures with fewer postoperative issues. The development of robot assisted urologic surgery systems has also led to improved endourology devices and advanced urological imaging systems which enable doctors to perform precise organ conserving procedures with shorter hospital stays and lower readmission rates thus creating strong motivation for providers to buy premium urology equipment.
02
Restraint: Escalating regulatory scrutiny and complex approvals delaying commercialization of innovative urology devices worldwide
The approval process for next generation urology devices becomes slower because of enhanced clinical evidence needs and post market monitoring requirements and data protection standards. The long duration of clinical trials for smart catheters and urological implants makes it difficult for small innovators to obtain funding which results in delayed product releases that extend beyond several years. The extended product launch delays prevent premium solutions from entering the market because older urology equipment platforms continue to win tenders which reduces market demand for premium solutions and enables large incumbent companies to maintain their market dominance through their ability to handle compliance expenses.
03
Opportunity: High growth in urology devices for urinary incontinence among women in Asia Pacific urban centers and Growing adoption of minimally invasive urology devices for ageing men in North America and Europe
The Asia Pacific cities experience changing healthcare needs because urbanization has increased female workers in the workforce and people have become more aware of their health. The combination of large untreated patient groups and insufficient specialized continence facilities makes urology consumables including disposable urology catheters and pessaries and their accessories attractive business opportunities. The global market for consumables and accessories reached 11.38 billion in 2024 and experts predict it will grow to 18.74 billion by 2030 at an 8.67% annual rate while showing the highest growth in high volume incontinence and pelvic floor care services.
The aging male population across these established markets continues to require urology devices which perform minimally invasive procedures for treating benign prostatic hyperplasia and prostate cancer and complex stone disease. The market potential exists for secondary and community hospitals to acquire advanced urology instruments which include flexible endoscopes and laser systems and image guided platforms. The global instrument market reached 23.32 billion in 2024 and experts predict it will reach 34.22 billion by 2030 with a 6.6% annual growth rate that will focus on high acuity therapeutic procedures.
04
Challenge: Intensifying cost pressures and reimbursement constraints reducing adoption of advanced digital and minimally invasive urology
The combination of hospital budget restrictions and low reimbursement rates for minimally invasive urology procedures and bundled payment systems drives buyers to select affordable endoscopic urology tools instead of advanced image guided and connected systems. The procurement team extends equipment replacement periods while focusing on fundamental capital assets and restricts the acquisition of high margin urology devices with software capabilities. The market shift toward price competition instead of technological advancement occurs because manufacturers face reduced profit margins and decreased sales of innovative platforms.
Supply Chain Landscape
1
Urology Catheters
BDB. Braun Melsungen AG
2
Urology Devices Manufacturing
Boston Scientific CorporationOlympus Corporation
3
Urological Equipment Distribution
Cardinal HealthBD
4
Clinical Renal Care
HospitalsAmbulatory surgical centersUrology clinics
1
Urology Catheters
BDB. Braun Melsungen AG
2
Urology Devices Manufacturing
Boston Scientific CorporationOlympus Corporation
3
Urological Equipment Distribution
Cardinal HealthBD
4
Clinical Renal Care
HospitalsAmbulatory surgical centersUrology clinics
Use Cases of Urology Devices in Kidney Diseases & Benign Prostatic Hyperplasia
Kidney Diseases : The urology device market depends on kidney disease treatment as hospitals and ambulatory surgical centers together with dialysis centers produce $24.81 billion and $3.92 billion in revenue for 2024 which will expand at 7.2% and 6.3% annual rates until 2030 because of rising chronic kidney disease rates. The medical field uses kidney disease management devices including dialysis catheters and drainage systems and ureteral stents and diagnostic endoscopes and monitoring platforms for patient care. The market shows instrument dominance at 67.2% while consumables and accessories follow at 32.80% which demonstrates the need for durable urology surgical instruments and recurring urology consumables. The solutions provide better vascular access safety and improved fluid management and prompt treatment for obstructive uropathy. The market leaders in catheter and vascular access technology include BD and B. Braun Melsungen AG while Cardinal Health leads urology consumable distribution through its contracting power and Boston Scientific Corporation and Olympus Corporation lead complex kidney and obstruction treatment through their advanced endoscopic urology devices which enable both diagnostic procedures and minimally invasive interventions.
Urological Cancer : The main factor driving hospitals and ambulatory surgical centers to purchase advanced urology equipment stems from the high incidence of urological cancers which require fast detection methods and preservation of organs. The main device categories for urological cancer treatment include oncologic endoscopes and resectoscopes and tumor ablation platforms and imaging systems and navigation tools and laser systems for precise tissue cutting and coagulation. The market shows instruments leading this application because they account for 67.2% of total demand while consumables and accessories make up 32.80% of the market. The technologies provide doctors with precise tumor detection capabilities and precise surgical removal methods and non invasive treatment options which result in shorter hospital stays and less blood loss and better patient function. The transition toward minimally invasive urology procedures in high volume surgical centers becomes more evident because of these technologies which provide accurate tumor visualization and targeted resection and minimally invasive therapy. Boston Scientific Corporation and Olympus Corporation maintain their market leadership through their complete range of endoscopic urology equipment and cancer focused intervention systems and imaging platforms. B. Braun Melsungen AG provides dependable surgical instruments to healthcare facilities while BD and Cardinal Health maintain oncologic care consistency through their high quality single use components and integrated supply capabilities.
Benign Prostatic Hyperplasia : The urology device market depends heavily on benign prostatic hyperplasia treatment because the rising number of aging men requires interventional solutions which hospitals and ambulatory surgical centers perform most procedures. The treatment of BPH requires clinicians to use transurethral resection systems and minimally invasive thermal and implant based platforms and visualization endoscopes and various catheters for bladder management during perioperative care. The device based treatment methods provide multiple benefits to patients because they deliver lasting symptom control and minimize pharmacological treatment duration and achieve faster recovery times with fewer complications than traditional open surgery methods. The adoption of minimally invasive urology devices for BPH treatment continues to grow because these devices provide better symptom control and shorter recovery times and lower complication rates than open surgery. Boston Scientific Corporation maintains its market leadership through its extensive range of minimally invasive BPH solutions and proven clinical data. Olympus Corporation provides advanced visualization and endoscopic technologies to enhance procedural precision while Boston Scientific Corporation and B. Braun Melsungen AG and Cardinal Health support the segment through their reliable instruments and urology consumables and extensive hospital contracting networks.
Recent Developments
The urology device industry shows fast paced development because of new minimally invasive urology technologies which focus on endoscopic systems and laser lithotripsy and robotic assisted surgery for treating kidney stones and prostate disorders. The development of urinary catheters and stents and incontinence management solutions now includes digital health capabilities and real time tracking systems. The market continues to move toward outpatient urology procedures which creates demand for affordable urology equipment and disposable medical devices.
January 2024 : Boston Scientific Corporation has reached a final agreement to acquire Axonics which develops sacral neuromodulation and urinary incontinence treatment technologies to expand its urology device and equipment offerings and enhance its minimally invasive urology market position and drive faster consolidation and innovation in neuromodulation based endourology therapies.
May 2023 : Boston Scientific Corporation launched LithoVue Elite single use digital flexible ureteroscope system for kidney stone interventions which provides real time intrarenal pressure monitoring and improved visualization through its urology devices portfolio to enhance endourology procedure efficiency and boost hospital and ambulatory surgery center adoption of disposable stone management tools and promote complex stone treatment with disposable scopes.
Impact of Industry Transitions on the Urology Devices Market
As a core segment of the Medical Device industry,
the Urology Devices market develops in line with broader industry shifts.
Over recent years, transitions such as Shift To Minimally Invasive Care and Digital Integration Across Care Pathways have redefined priorities
across the Medical Device sector,
influencing how the Urology Devices market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift To Minimally Invasive Care
The Urology Devices market is undergoing a significant transition towards minimally invasive and day case procedures, driven by a healthcare landscape that increasingly favors patient centric care and operational efficiency. This shift is expected to generate an additional $4 billion in market growth by 2030, as demand surges for advanced technologies such as flexible ureteroscopes, laser lithotripsy systems, and disposable endoscopic equipment. Concurrently, the rise of ambulatory surgical centers, bolstered by strategic hospital procurement initiatives, enhances recovery times and minimizes complications. Vendors are responding by adopting standardized minimally invasive platforms, facilitating the development of cross specialty towers that integrate energy devices and imaging systems. This strategic alignment not only maximizes operating room utilization but also significantly reduces capital expenses, positioning the Urology Devices market for robust growth in the coming years. This industry transition is expected to add $5 billion in the industry revenue between 2024 and 2030.
02
Digital Integration Across Care Pathways
The integration of digital technologies runs parallel to urology device development because smart hospitals and remote care models require data generating tools and connected medical devices. The integration of AI powered diagnostic systems into urological imaging systems and bladder monitoring solutions and connected catheters enables predictive maintenance and real time decision support and personalized treatment plans. The digital transformation affects radiology and nephrology and oncology operations because telehealth integration with interoperable platforms enables teams to exchange data and coordinate complex cases and improve chronic kidney disease and prostate cancer management.